Phathom Pharmaceuticals, Inc. ROA

ROA of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROA growth rates and interactive chart. Return on Assets (ROA) is an indicator of how well a company utilizes its assets, by determining how profitable a company is relative to its total assets. A company with $1 million in net income and $10 million in average assets will have a 10% ROA.

Highlights and Quick Summary

  • Annual ROA for 2020 was -46.74% (a -76.36% decrease from previous year)
  • Annual ROA for 2019 was -197.71% (a -Infinity% decrease from previous year)
  • Twelve month ROA ending June 29, 2021 was -68.19% (a 21.01% increase compared to previous quarter)
  • Twelve month trailing ROA decreased by -38.91% year-over-year
Trailing ROA for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-68.19% -56.35% -46.74% -111.63%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROA of Phathom Pharmaceuticals, Inc.

Most recent ROAof PHAT including historical data for past 10 years.

Interactive Chart of ROA of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. ROA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 – – – – -46.74%
2019 – – – – -197.71%
2018 – – – – 0.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
© stockrow.com